Key result
DOCA-salt elevates blood pressure via initial potassium and water loss before secondary sodium retention.
Why the study?
While Na+ and water overload from low renal excretion is considered the root cause of salt-sensitive hypertension, experimental renal and psoriasis hypertension feature a chronic predisposition to dehydration. The validity of this alternative water-loss theory in deoxycorticosterone acetate (DOCA) salt-sensitive hypertension required testing.
Does deoxycorticosterone acetate (DOCA) with NaCl or NaHCO3 alter body Na+, K+, water content, and blood pressure in mice on a low Na+ diet?
Does deoxycorticosterone acetate (DOCA) with NaCl or NaHCO3 alter body Na+, K+, water content, and blood pressure in mice on a low Na+ diet?
Experimental DOCA salt-sensitive hypertension initiates with K+-driven intracellular water loss and a systemic water conservation response rather than primary Na+ and water overload, which can be treated by oral K+ supplementation.
Supports water-loss hypothesis in DOCA model on low-Na diet; hypothesis-generating, requires human validation.
BACKGROUND: Na + and water overload due to inappropriately low renal salt and water excretion is considered the root cause of salt-sensitive hypertension. However, experimental renal and psoriasis hypertension are characterized by chronic predisposition to dehydration. We tested the validity of this alternative hypertension due to loss of water theory in deoxycorticosterone acetate (DOCA) salt-sensitive hypertension. METHODS: We tested the effect of DOCA (25 mg pellet) in mice on a low Na + diet (0.02%–0.03%) with tap water, or with Na + in their drinking water (1% NaCl or 1.44% NaHCO 3 ), on body Na + , K + , and water content 2, 6, and 12 days after treatment initiation. We monitored blood pressure with radio-telemetry, food and water intake, and renal electrolyte and water excretion. RESULTS: At day 2, DOCA NaCl-treated mice elevated blood pressure during a state of isolated body K + and water loss, indicating substantial intracellular dehydration. Although increasing their fluid intake and urine output, the mice reduced the excretion of free water, indicating renal water conservation. At days 6 and 12, secondary Na + retention occurred, which replaced the amount of K + lost and corrected the dehydration, albeit at the expense of an intracellular Na + /K + redistribution disorder. DOCA NaHCO 3 -treated mice with Na + -resistant blood pressure showed a comparable Na + /K + redistribution disorder, but without accompanying early dehydration due to earlier replacement of lost K + by Na + . CONCLUSIONS: Experimental DOCA salt-sensitive hypertension initiates with a systemic water conservation response in the face of K + -driven intracellular water loss. Both dehydration and blood pressure increase could be causally treated by oral K + supplementation.
No takes yet. Share an insight, caveat, or question.
Minegishi et al. (2026) studied Experimental DOCA salt-sensitive hypertension. Deoxycorticosterone acetate (DOCA) with 1% NaCl or 1.44% NaHCO3 drinking water vs. DOCA (25 mg pellet) on a low Na+ diet (0.02%–0.03%) with tap water was evaluated on Body Na+, K+, and water content, blood pressure, food and water intake, and renal electrolyte and water excretion. DOCA (25 mg) with 1% NaCl in mice elevated blood pressure at day 2 via isolated K+ and water loss (intracellular dehydration), followed by secondary Na+ retention at days 6 and 12.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: